dabigatran etexilate / Generic mfg. - LARVOL DELTA

Direct Oral Anticoagulants Versus Warfarin in Antiphospholipid Syndrome: A Propensity-Matched Real-World Analysis of Recurrent Thrombosis, Bleeding, and Mortality (ACR Convergence 2026) - "Adults with APS (ICD-10 D68.61; cohorts defined by ICD-10 coding rather thanclassification criteria) were assigned to DOAC (apixaban or rivaroxaban) or warfarin; each cohortexcluded exposure to the comparator and to other anticoagulants (dabigatran, edoxaban,enoxaparin) to prevent crossover. The index was first qualified for anticoagulant exposure.Propensity score matching (1:1) balanced demographics and a broad covariate set includinghypertension, CKD, SLE, prior venous and arterial thromboembolism (DVT/PE, cerebral infarction),prior myocardial infarction (MI), thrombocytopenia/purpura, prior major bleeding (intracranial, GI,posthemorrhagic anemia), and hydroxychloroquine use, yielding 7,074 matched patients per cohort(all post-match SMD < 0.05)... In this large active-comparator real-world APS cohort, DOAC initiators had significantlyhigher recurrent venous thromboembolism (PE and DVT) than warfarin initiators, consistent withreduced DOAC efficacy for thrombosis..."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Genetic Disorders • Hematological Disorders • Hypertension • Inflammatory Arthritis • Ischemic stroke • Myocardial Infarction • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • Venous Thromboembolism

Direct Oral Anticoagulants vs. Standard of Care in Nephrotic Syndrome (KIDNEY WEEK 2026) - "DOAC agents included rivaroxaban, dabigatran, and apixaban...Al Jurdi 2023 observed 0 events with apixaban versus 1 with warfarin (log-rank p=0.041)...Overall certainty is low due to study design and sparse reporting. Prospective randomized trials are needed to clarify the balance between thrombotic prevention vs bleeding risk in NS."

Cardiovascular • Glomerulonephritis • Hematological Disorders • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases

Renoprotective Effects of Direct Oral Anticoagulants in Glomerular Diseases (KIDNEY WEEK 2026) - "Following disease induction rats received daily oral rivaroxaban (riva; 3 mg/kg), dabigatran (dabi; 20 mg/kg), or sham, and were compared to healthy controls (n=4-11/group). Conclusion DOAC therapy may provide a novel approach to ameliorate glomerular disease progression while simultaneously reducing thromboembolic risk, a life-threatening complication of glomerular disease. Importantly, the chronic model data demonstrates that DOACs are renoprotective when started after proteinuria is established."

Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Infectious Disease • Renal Disease • Thrombosis

Anticoagulant-Related Nephropathy: A Diagnostic Challenge in the Setting of Leukocytoclastic Vasculitis (KIDNEY WEEK 2026) - "Although it has been mostly described with warfarin, there is growing recognition that direct oral anticoagulants (DOACs) may also play a role...Dabigatran was replaced by apixaban, and his rash improved over several weeks...Discussion ARN can be difficult to recognize when multiple competing causes of AKI are present, given increasing evidence that DOACs may cause ARN. ARN should be considered in patients with AKI and gross hematuria receiving DOAC therapy, especially when the clinical picture is unclear."

Acute Kidney Injury • ANCA Vasculitis • Atrial Fibrillation • Cardiovascular • Diabetes • Hematological Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Renal Disease • Septic Shock • Type 2 Diabetes Mellitus • Vasculitis

Clinical Drug-Drug Interaction Profile Of BIA 28-6156: Results From Three Independent Phase I Studies (MDS Congress 2026) - " Interactions between BIA 28-6156 and mechanistically relevant drugs, namely strong CYP3A4 modulators (carbamazepine and clarithromycin), index CYP3A4 substrate (midazolam), and BCRP-, MATE1- and P-gp substrates (rosuvastatin, metformin, and dabigatran etexilate, respectively), were evaluated in healthy subjects [Figure 1]. As a substrate, strong CYP3A4 modulators impact the exposure of BIA 28-6156. As a precipitant, BIA 28-6156 has no effect on CYP3A4 activity. BIA 28-6156 may inhibit BCRP and P-gp-mediated drug transport."

Clinical • P1 data • CNS Disorders • Movement Disorders • Parkinson's Disease • CYP3A4 • GBA

Perioperative Outcomes of Direct Oral Anticoagulant Use in Mohs Micrographic Surgery: A Propensity-Matched Analysis (EADV 2026) - "Patients undergoing MMS were stratified by perioperative DOAC use (apixaban, rivaroxaban, dabigatran, or edoxaban) versus no anticoagulant or antiplatelet therapy. Conclusions Perioperative DOAC use in MMS is associated with increased risks of bleeding, thromboembolic events, and healthcare utilization without increased infection risk. The rarity of mortality events underscores the overall short-term safety of MMS and supports individualized perioperative anticoagulation management."

Surgery • Cardiovascular • Hematological Disorders • Infectious Disease • Thrombosis

DNA Damage and Micronucleus Induction by Small-Molecule Nitrosamine Drug Impurities and Nitrosamine Drug Substance-Related Impurities in HepaRG Cells. (PubMed, Environ Mol Mutagen) - "The genotoxicity of four small-molecule nitrosamines, N-bis(2,2-diethoxyethyl) nitrous amide (BDEA), N-nitrosodiphenylamine, N,N-nitroso-N-ethylaniline (NEPA), and 1-methyl-4-nitrosopiperazine (MNP), and five NDSRIs, N-nitroso-bumetanide, N-nitroso-ciprofloxacin, N-nitroso-dabigatran etexilate, N-nitroso-desmethyl-diphenhydramine, and N-nitroso-sertraline, was evaluated in two-dimensional (2D)/attached and three-dimensional (3D)/spheroid HepaRG cell cultures using two high-throughput genetic toxicity assays, the CometChip DNA damage assay and the flow-cytometric micronucleus (MN) assay. Benchmark concentration (BMC) values derived from the DNA damage data were lower for the genotoxic NDSRIs compared to the genotoxic small-molecule nitrosamines, which correlated with higher cytotoxicity for the NDSRIs. These results show that, while HepaRG spheroids were a more sensitive model for the hazard identification of small-molecule nitrosamines, the responses produced by NDSRIs..."

Journal

Dabigatran's Anti-Metastatic Properties for Improved Long-Term Cancer Prognosis: A Critical Review. (PubMed, Curr Probl Cardiol) - "However, its effects on metastasis are inconsistent across cancer types. While brain metastasis models show that dabigatran reduces tumor cell extravasation by inhibiting thrombin-mediated clot formation, triple-negative breast cancer (TNBC) models report no significant effect on tumor growth or metastasis."

Journal • Review • Breast Cancer • Colorectal Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer

Evaluating the Impact of Therapeutic Anticoagulation Management in Head and Neck Free Tissue Transfer: A Retrospective Study of 126 Cases. (PubMed, Microsurgery) - "This study highlights the challenges of managing therapeutic anticoagulation in head and neck free flap surgery, where thromboembolic risk during interruption and hemorrhagic complications upon resumption point to the need for clearer guidelines. Evidence-based protocols are needed to replace discretionary practices and improve outcomes."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Otorhinolaryngology • Venous Thromboembolism

Acute Median Neuropathy Due to Persistent Median Artery Thrombosis Following Cupping Therapy: The Diagnostic Value of High-Resolution Ultrasound. (PubMed, Cureus) - "Anticoagulation with enoxaparin followed by dabigatran etexilate resulted in substantial pain relief. This report demonstrates the value of high-resolution gray-scale and Doppler ultrasonography for identifying PMA thrombosis, characterizing arterial occlusion, and assessing associated median nerve and distal vascular involvement. PMA thrombosis should be considered in rapidly progressive median neuropathy accompanied by severe pain, distal coldness, or other signs of vascular compromise."

Journal • Cardiovascular • Dermatology • Hematological Disorders • Musculoskeletal Pain • Pain • Thrombosis

POLYGLYCOLIC ACID SHEET AND FIBRIN GLUE SHIELDING FOR PREVENTION OF POST-ESD BLEEDING IN PATIENTS RECEIVING ANTICOAGULANTS OR DUAL ANTIPLATELET THERAPY: A PROSPECTIVE MULTICENTER STUDY (UEGW 2026) - "The risk is substantially higher, reported about 10-20% of patients receiving dual antiplatelet therapy (DAPT) or anticoagulants, including warfarin and direct oral anticoagulants (DOACs), and more effective preventive strategies are needed for these high-risk patients...Among DOAC users, 47 received edoxaban, 7 dabigatran, 31 rivaroxaban, and 26 apixaban... This prospective multicenter study evaluated PGA sheet and fibrin glue shielding in patients at high risk of post-ESD bleeding due to anticoagulant use or DAPT. Although the delayed bleeding rate was below the prespecified threshold of 15%, statistical significance was not achieved. The observed bleeding rate was numerically lower than previously reported rates in similar high-risk populations, suggesting that this shielding method may be a promising preventive strategy."

Clinical • Gastric Adenocarcinoma • Gastric Cancer • Solid Tumor

OPTIMAL TIMING OF RESUMING ANTICOAGULANTS AFTER COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION (UEGW 2026) - "Propensity score matching (PSM) was used to compare delayed bleeding rates in the overall, DOAC, and warfarin cohorts...Other DOACs, including edoxaban, apixaban, and rivaroxaban, showed more stable safety profiles regardless of renal function. The early resumption of anticoagulants within 1 day post-ESD did not significantly increase delayed bleeding. However, our findings highlight the necessity of an individualized approach; specifically, extreme caution is required when resuming dabigatran early in patients with renal impairment."

Cardiovascular • Renal Disease

APPLICATION OF TRANSJUGULAR EXTRAHEPATIC PORTOSYSTEMIC SHUNT FOR CAVERNOUS TRANSFORMATION OF PORTAL VEIN AFTER SURGICAL SHUNT FAILURE (UEGW 2026) - "The patient received dabigatran anticoagulation therapy after the surgery...This case underscores that for patients with CTPV, a minimally invasive, interventional approach should be strongly considered as a first-line strategy - particularly in complex cases - rather than reserving it as a salvage option after surgical failure. Early referral and comprehensive evaluation could allow for optimal treatment planning, potentially avoiding surgical morbidity and offering patients a more rational, patient-centered pathway."

Cardiovascular • Hepatology • Portal Hypertension

Basic Periodontal Treatment Improves Periodontal Inflamed Surface Area Without Adverse Events in Patients Receiving Direct Oral Anticoagulants: A Retrospective Clinical Study with an Animal Model. (PubMed, Biomedicines) - " This retrospective study included 67 patients receiving continuous DOAC therapy (edoxaban, apixaban, dabigatran, or rivaroxaban) who underwent nonsurgical periodontal treatment without drug discontinuation. Basic periodontal treatment appears to be safe and effective for patients prescribed DOACs and may reduce local periodontal inflammation, resulting in systemic inflammatory burden. These findings support proactive periodontal intervention in patients receiving DOAC therapy, regardless of the specific anticoagulant used."

Adverse events • Journal • Preclinical • Retrospective data • Dental Disorders • Inflammation • Osteoporosis • Periodontitis • IL10 • IL1B • IL4 • IL6

Pharmacokinetic Variability of Direct Oral Anticoagulants and Calcium Channel Blockers: A Comparative Analysis of Exposure Data from Clinical Studies. (PubMed, Pharmaceutics) - "Among DOACs, edoxaban exhibited the lowest PK variability, whereas dabigatran showed the highest. CCBs demonstrated a broad variability spectrum, ranging from predictable agents (amlodipine and felodipine) to highly variable compounds (nisoldipine, isradipine, nimodipine, diltiazem, and verapamil)... These findings suggest that fixed-dose strategies may not be universally appropriate for DOACs and CCBs, particularly in high-risk subgroups where altered exposure may lead to sub- or supratherapeutic concentrations and compromise clinical outcomes. Therefore, clinicians should avoid evaluating individual risk factors in isolation and instead consider the patient's complete profile when selecting and adjusting pharmacotherapy."

Journal • PK/PD data

Temporal Trends in Anticoagulant Prescribing in Patients with Atrial Fibrillation According to Prior Ischemic Stroke or Transient Ischemic Attack: Insights from the CRAFT Registry. (PubMed, J Clin Med) - "However, it was associated with overall DOAC molecule selection (global p = 0.0013), driven by a greater likelihood of dabigatran versus apixaban prescribing (RRR 1.87, 95% CI 1.29-2.72; q = 0.0052). In exploratory dose-specific analyses, prior stroke/TIA was associated with a lower likelihood of rivaroxaban 20 versus 15 mg prescribing (OR 0.54, 95% CI 0.33-0.90; q = 0.047)...Prior ischemic stroke/TIA was not independently associated with OAC use or DOAC versus VKA selection and did not significantly modify temporal prescribing trends, although differences were observed in DOAC molecule selection and exploratory dose-specific prescribing. Dose-specific findings describe prescribing patterns and should not be interpreted as assessments of dose appropriateness, efficacy, or safety."

Journal • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Ischemic stroke • Metabolic Disorders

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Deciphera Pharmaceuticals, LLC | Not yet recruiting ➔ Recruiting

Enrollment open

Design and evaluation of deep eutectic solvent system for dabigatran etixilate. (PubMed, J Pharm Sci) - "Accelerated stability confirmed the formulation meets regulatory shelf limits, maintaining over 95% chemical recovery for six months. The developed DES systems effectively resolved Dabigatran Etexilate solubility challenges, highlighting their potential for enhancing BCS Class II and IV drug delivery."

Journal

Central Composite Design-Optimized Dabigatran Etexilate Cubosomes for Sustained Oral Release and Enhanced In Vivo Pharmacokinetics. (PubMed, Pharm Res) - "The optimized cubosomal system effectively improved the oral delivery and sustained release of DEM. The formulation demonstrated enhanced relative bioavailability and prolonged systemic exposure, supporting further development for oral DEM delivery. Anticoagulant efficacy, gastrointestinal safety, and appropriate dosing regimens remain to be established."

Journal • PK/PD data • Preclinical • Atrial Fibrillation • Cardiovascular

Concurrent Aspirin Use in Anticoagulated Patients and Risk of Gastrointestinal Bleeding: A Propensity-Score-Matched Cohort Analysis (ACG 2026) - "Cohort 1 comprised adults on chronic anticoagulation (apixaban, rivaroxaban, dabigatran, edoxaban, or warfarin) with concurrent aspirin use; Cohort 2 comprised anticoagulated adults without aspirin. Post-PSM cohorts were well-balanced (all SMDs < 0.003). Aspirin use was associated with significantly higher rates of upper GI bleed (1.51% vs. 1.26%; HR 1.34, 95% CI 1.20â1.48; p< 0.001), unspecified GI hemorrhage (1.39% vs."

Clinical • Cardiovascular • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Renal Disease • Thrombocytopenia

Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Cardiovascular Outcomes in Diabetes Patients with Atrial Fibrillation: A Single-Center Experience. (PubMed, Acta Cardiol Sin) - "This retrospective cohort study included patients with DM and AF treated with NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) between December 2012 and June 2022 at a tertiary hospital in Taiwan. In this single-center study, the risk of major bleeding was similar across the four NOACs. In addition, dabigatran was associated with lower risks of MACEs and all-cause mortality compared with apixaban."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Gastroenterology • Hematological Disorders • Ischemic stroke • Metabolic Disorders • Myocardial Infarction

Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study. (PubMed, J Cardiovasc Pharmacol Ther) - "Adherence levels for dabigatran, rivaroxaban, apixaban, and edoxaban were compared at 3, 6, 9, and 12 months. The NVBP policy improves adherence short-term, but long-term effects are limited. Targeted interventions are necessary for high-risk populations."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders

A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: BeOne Medicines

New P1 trial

Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial. (PubMed, Cardiol J) - P4 | "ADONIS-PCI is among the first randomized evaluations of a reduced-dose long-term ticagrelor strategy combined with dabigatran in patients with AF and ACS undergoing PCI. The trial addresses an important evidence gap in the selection and dosing of P2Y12 inhibition when aspirin is discontinued early in this high-risk population."

Clinical protocol • Journal • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Myocardial Infarction

Dabigatran Attenuates Osteoporosis by Balancing Osteoblastogenesis and Osteoclastogenesis by Targeting PRKAB1 and RELA. (PubMed, Research (Wash D C)) - "Imbalances between osteoblastogenesis and osteoclastogenesis represent the fundamental pathological feature of primary osteoporosis; however, safe and cost-effective therapies that simultaneously promote bone formation and suppress bone resorption are lacking. In bone marrow mesenchymal stem cells, DAB binds to protein kinase adenosine-monophosphate-activated noncatalytic subunit β1 via the alanine-77 residue, leading to adenosine-monophosphate-activated protein kinase activation, subsequent mechanistic target of rapamycin complex 1 inhibition, enhanced autophagic flux, and ultimately promoted osteogenesis; in osteoclast precursors, DAB interacts with v-Rel reticuloendotheliosis viral oncogene homolog A at arginine-50, resulting in suppression of the nuclear factor κB pathway and attenuated osteoclast differentiation. Collectively, our findings reposition DAB as a promising therapeutic candidate for restoring osteoblast-osteoclast balance and maintaining skeletal..."

Journal • Metabolic Disorders • Oncology • Osteoporosis • Rheumatology • Targeted Protein Degradation • PRKAB1 • RELA